Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same author

Comparative Outcomes of Ultrasound-Assisted Thrombolysis and Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism.

Journal of clinical medicine·2026
Same author

Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study.

Pathologica·2026
Same author

Type 2 Myocardial Infarction: Navigating Diagnostic Pathways and Therapeutic Crossroads Between Invasive and Conservative Strategies.

Journal of clinical medicine·2026
Same author

Improving end-of-life care in the cardiac intensive care unit: Navigating the challenge of timing palliative care intervention.

European journal of clinical investigation·2026
Same author

[Clear Pathway: the role of bempedoic acid in lipid-lowering strategies. The opinion of cardiologists from Piedmont and Aosta Valley, Italy].

Giornale italiano di cardiologia (2006)·2026

Related Experiment Video

Updated: Jun 26, 2026

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Coronary-Bronchial Artery Fistulas: Pathophysiology, Multimodality Imaging, and Contemporary Management.

Andrea Falcetta1, Francesca Giordana1, Paolo Desalvo1

  • 1Cardiology and Intensive Coronary Care Unit Department, Santa Croce e Carle Hospital, 12100 Cuneo, Italy.

Journal of Cardiovascular Development and Disease
|June 25, 2026
PubMed
Summary

Coronary-bronchial artery fistulas (CBAFs) are rare but increasingly recognized. Management depends on size and symptoms, ranging from observation to intervention.

Keywords:
coronary artery fistulascoronary–bronchial artery fistulasdiagnosispathophysiologytreatment

Related Experiment Videos

Last Updated: Jun 26, 2026

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Area of Science:

  • Cardiology
  • Radiology
  • Thoracic Surgery

Background:

  • Coronary-bronchial artery fistulas (CBAFs) are uncommon anomalies.
  • Historically incidental, increased imaging use reveals more CBAFs.
  • Clinical significance varies with size, shunt, and cardiopulmonary status.

Purpose of the Study:

  • Provide an updated overview of CBAFs.
  • Emphasize size-based stratification and multimodality imaging.
  • Offer a practical framework for diagnosis and management.

Main Methods:

  • Literature review focusing on epidemiology, pathophysiology, diagnosis, and management.
  • Integration of multimodality cardiovascular imaging (e.g., CCT angiography).
  • Discussion of diagnostic tools including imaging and hemodynamic assessment.

Main Results:

  • CBAFs can cause myocardial ischemia, ventricular remodeling, and hemoptysis.
  • Small, asymptomatic fistulas may require surveillance.
  • Larger or hemodynamically significant fistulas may need percutaneous or surgical closure.

Conclusions:

  • CBAFs require a comprehensive, multimodality evaluation.
  • Size-based stratification guides clinical management.
  • Timely diagnosis and appropriate management are crucial for patient outcomes.